Drug Overview

The HER2-targeted liposomal doxorubicin hydrochloride MM-302 (also referred to simply as MM-302) is an investigational “immunoliposome”—a sophisticated drug delivery system that combines the potency of chemotherapy with the precision of targeted therapy. It consists of the chemotherapy drug doxorubicin encapsulated in a lipid sphere (liposome), which is “decorated” on its surface with single-chain antibodies that specifically seek out the HER2 receptor.

Developed by Merrimack Pharmaceuticals, MM-302 was designed to overcome the “cardiotoxicity” (heart damage) typically associated with anthracyclines like doxorubicin, while ensuring the drug reaches high concentrations directly inside HER2-positive breast cancer cells. By using a liposomal shell, the drug is shielded from healthy tissues, particularly the heart, until it reaches the tumor.

Generic Name: MM-302.
Drug Class: Targeted Liposomal Anthracycline / Antibody-Drug Conjugate (ADC) Variant.
Target: HER2 (ERBB2) receptor (specifically Subdomain I).
Payload: Doxorubicin hydrochloride.
Route of Administration: Intravenous (IV) infusion.
FDA Approval Status: Investigational/Discontinued. As of March 2026, MM-302 is no longer in active clinical development. In late 2016, the pivotal Phase II HERMIONE trial was halted because the drug did not show a significant benefit over standard treatments. While the molecule remains a landmark in “nanomedicine” research, it has been largely superseded by newer Antibody-Drug Conjugates like Enhertu.

What Is It and How Does It Work? (Mechanism of Action)

HER2-targeted liposomal doxorubicin hydrochloride MM-302 2

MM-302 operates as a “Trojan Horse,” using the HER2 receptor as a gateway to deliver a lethal dose of chemotherapy directly into the tumor cell.

The Antibody-Liposome Structure

MM-302 is composed of approximately 20,000 molecules of doxorubicin safely tucked inside a PEGylated liposome. On the surface of this liposome are dozens of “single-chain” antibodies (scFv) that specifically bind to subdomain I of the HER2 receptor. This is a different binding site than that of trastuzumab (Herceptin), allowing the two to be used together without competing for the same spot on the receptor.

Molecular Level Mechanisms

Selective Homing: Once infused, the liposomes circulate in the blood. Because of their size, they “leak” out specifically in tumors where blood vessels are porous—a phenomenon known as the Enhanced Permeability and Retention (EPR) effect.
Receptor Binding: The antibodies on the MM-302 surface latch onto HER2 receptors. Research shows a “threshold” of roughly 200,000 receptors per cell is needed for efficient binding, which helps spare healthy cells with lower HER2 levels.
Endocytosis: Once bound, the cancer cell “swallows” the entire liposome in a process called receptor-mediated endocytosis.
Intracellular Release: Inside the cell’s acidic environment, the liposome breaks down, releasing the doxorubicin payload.
DNA Destruction: The doxorubicin travels to the cell nucleus, where it intercalates (inserts itself) into the DNA and inhibits topoisomerase II. This prevents the cancer cell from repairing its DNA or replicating, leading to rapid cell death.

Dosage and Administration Protocols

During its clinical development, MM-302 was studied both as a single agent and in various combinations. The following protocols were established during the Phase I and Phase II trials to determine the optimal therapeutic window.

Phase I Dose Escalation

In the initial safety studies, researchers explored a wide range of doses to find the Maximum Tolerated Dose (MTD).

Monotherapy: Doses of 8, 16, 30, 40, and 50 mg/m² were administered every 4 weeks (q4w).
Combination with Trastuzumab: Studied at 30 or 40 mg/m² every 4 weeks, paired with a maintenance dose of trastuzumab (6 mg/kg) every 3 weeks.
Triple Combination: MM-302 (30 mg/m²) was also tested alongside trastuzumab and cyclophosphamide (450 mg/m²) on a 21-day cycle.

Phase II “HERMIONE” Protocol

For the pivotal Phase II trial, the dosing was standardized to maximize the “drug intensity” while managing side effects:

MM-302 Dose: 30 mg/m² administered as an IV infusion.
Frequency: Once every 21 days (3-week cycle).
Combination: Administered in tandem with Trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg maintenance every 3 weeks).
Modifications: Protocols allowed for two dose reductions (to 22.5 mg/m² and then 15 mg/m²) to manage hematologic toxicities like neutropenia or non-hematologic events like hand-foot syndrome.

Clinical Research and The HERMIONE Trial

The most significant data regarding MM-302 came from the Phase II HERMIONE study (NCT02213744), which focused on patients who were “anthracycline-naïve” (had never received doxorubicin) but had failed other HER2 therapies.

Trial Design: The study compared MM-302 (plus trastuzumab) against “Physician’s Choice” chemotherapy (gemcitabine, capecitabine, or vinorelbine) plus trastuzumab.
The Outcome: An independent data monitoring committee found that MM-302 did not significantly extend Progression-Free Survival (PFS). Both the experimental and control arms showed shorter-than-expected survival, and the trial was halted for futility in December 2016.
Historical Impact: Despite the failure to reach its primary endpoint, MM-302 proved that it could deliver doxorubicin without causing the severe heart damage usually seen with the drug, validating the “safety” of the targeted liposomal platform.

Safety Profile and Side Effects

A primary goal of MM-302 was to reduce toxicity, particularly to the heart and bone marrow.

Common Side Effects:

Fatigue: Reported by over 40% of patients in clinical trials.
Nausea: Generally manageable with standard anti-emetics.
Neutropenia: A drop in white blood cell counts, though Grade 3/4 neutropenia was less frequent than with standard doxorubicin.
Stomatitis: Mouth sores or inflammation, often linked to the PEGylated coating of the liposome.

Serious Risks:

Hand-Foot Syndrome (PPE): Redness, tingling, and peeling of the skin on the palms and soles.
Infusion Reactions: Allergic-type reactions occurring during the 60-minute IV administration.
Cardiac Monitoring: While MM-302 was designed to be “cardio-protective,” patients still required an LVEF (Left Ventricular Ejection Fraction) of $\ge 50\%$ to start treatment and regular monitoring thereafter.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, MM-302 has been used as a model for “Targeted Nanoparticle Dynamics.” Researchers used a radioactive tracer version of the drug (64Cu-MM-302) and PET/CT scans to watch exactly how the drug travels in the human body. This research is now being used to design better stem cell “homing” therapies—using similar antibody “decorations” to guide healthy stem cells to areas of the heart or brain that need regeneration after injury or disease.

Patient Management and Practical Recommendations

Pre-treatment (Historic Protocol):

HER2 Testing: Confirmation of HER2 overexpression (3+ or FISH positive).
Cardiac Screening: A baseline MUGA scan or echocardiogram.
Liver Function: Dose adjustments were required if total bilirubin was $> 1.2$ mg/dL.

“Do’s and Don’ts”:

DO understand that while MM-302 development has paused, the concept of Antibody-Drug Conjugates (ADCs) is currently the most successful area of breast cancer research.
DO discuss modern alternatives like Enhertu (Trastuzumab deruxtecan) with your oncologist, as these use similar “targeted delivery” technology.
DON’T seek out MM-302 in 2026, as it is no longer available in clinical trials.
DON’T ignore symptoms of hand-foot syndrome; early cooling of the limbs and the use of urea-based creams can mitigate skin damage.

Legal Disclaimer

The information provided is for educational and historical purposes only and does not constitute medical advice. MM-302 is an investigational agent that is no longer in active clinical development and is not FDA-approved. Always consult with a qualified oncologist regarding your diagnosis and the most current, FDA-approved treatment options for HER2-positive breast cancer.